News · 26 weeks47-17%
2026-03-012026-08-23
Mix1290d
- SEC Filings3(25%)
- Insider3(25%)
- Other2(17%)
- Earnings2(17%)
- Analyst2(17%)
Latest news
25 items- ANALYSTWells Fargo resumed coverage on Banc of California with a new price targetWells Fargo resumed coverage of Banc of California with a rating of Overweight and set a new price target of $23.00
- SECSEC Form 10-Q filed by Banc of California Inc.10-Q - BANC OF CALIFORNIA, INC. (0001169770) (Filer)
- PRBanc of California, Inc. Announces Quarterly DividendsBanc of California, Inc. (the "Company") (NYSE:BANC) announced today that its Board of Directors declared a quarterly cash dividend of $0.12 per share on its outstanding common stock. The dividend will be payable October 1, 2026, to stockholders of record as of September 15, 2026. The Board of Directors also declared a quarterly cash dividend of $0.4845 per depositary share on its 7.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series F. The dividend will be payable September 1, 2026, to stockholders of record as of August 20, 2026. The Series F depositary shares are traded on the New York Stock Exchange under the "Banc/PF" symbol. The Company maintains a Dividend Reinvestmen
- INSIDERCHIEF RISK OFFICER Lindsay Olivia I sold $117,030 worth of shares (6,000 units at $19.50), decreasing direct ownership by 15% to 32,842 units (SEC Form 4)4 - BANC OF CALIFORNIA, INC. (0001169770) (Issuer)
- INSIDERCHIEF FINANCIAL OFFICER Kauder Joseph covered exercise/tax liability with 5,444 shares, decreasing direct ownership by 8% to 60,361 units (SEC Form 4)4 - BANC OF CALIFORNIA, INC. (0001169770) (Issuer)
- ANALYSTBanc of California downgraded by Brean CapitalBrean Capital downgraded Banc of California from Buy to Neutral
- SECBanc of California Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits8-K - BANC OF CALIFORNIA, INC. (0001169770) (Filer)
- PRBanc of California, Inc. Reports Second Quarter 2026 Financial Results and Announces Strategic Balance Sheet Repositioning to Enhance Long-Term EarningsBanc of California, Inc. (NYSE:BANC): Quarter Results 9% Loan Average Annualized Growth 12% Deposit Annualized Growth $2.3 billion Securities Repositioning $18.38 Book Value Per Share $16.44 Tangible Book Value Per Share(1) $(1.61) Loss Per Share Banc of California, Inc. (NYSE:BANC) ("Banc of California" or the "Company"), the parent company of wholly-owned subsidiary Banc of California (the "Bank"), today reported financial results for the second quarter ended June 30, 2026. During the second quarter, t
- PRBanc of California Announces Schedule of Second Quarter 2026 Earnings Release and Conference CallBanc of California, Inc. (the "Company") (NYSE:BANC) today announced it will release financial results for the second quarter ended June 30, 2026 before the market opens on Wednesday, July 29, 2026. The Company will host a conference call to discuss these financial results the same day at 8:00 a.m. Pacific Time (PT). Interested parties are welcome to attend the conference call by dialing (888) 317-6003 and referencing event code 9364475. A link to the live audio webcast and the slide presentation for the call will be available on the Company’s investor relations website prior to the call. An audio archive of the conference call will be available on the Company’s investor relations website
- INSIDERSR EVP AND VICE CHAIRMAN Rice Joseph J was granted 18,114 shares, increasing direct ownership by 69% to 44,531 units (SEC Form 4)4 - BANC OF CALIFORNIA, INC. (0001169770) (Issuer)
- PRAllotera Therapeutics (Formerly Wugen) Closes $35 Million Financing to Advance Off-the-Shelf CAR-T Therapies for T-Cell CancersAdditional capital brings total raised to $150 million in a Series C financing Funds support pivotal-stage development of Soficabtagene Geleucel, an off-the-shelf CAR-T cell therapy being evaluated in relapsed or refractory T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma (T-LBL) New Allotera name reflects the company’s focus on advancing allogeneic cell therapies for patients with aggressive blood cancers Allotera Therapeutics, Inc. (formerly Wugen, Inc.), a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies for hematological malignancies, today announced the successful closing of a $35 million financing round
- SECSEC Form 144 filed by Banc of California Inc.144 - BANC OF CALIFORNIA, INC. (0001169770) (Subject)
- INSIDERCHIEF CREDIT OFFICER Corsini Bryan M sold $285,731 worth of shares (14,988 units at $19.06), decreasing direct ownership by 20% to 59,045 units (SEC Form 4)4 - BANC OF CALIFORNIA, INC. (0001169770) (Issuer)
- SECSEC Form 144 filed by Banc of California Inc.144 - BANC OF CALIFORNIA, INC. (0001169770) (Subject)
- INSIDERCHIEF CREDIT OFFICER Corsini Bryan M covered exercise/tax liability with 9,677 shares, decreasing direct ownership by 12% to 74,033 units (SEC Form 4)4 - BANC OF CALIFORNIA, INC. (0001169770) (Issuer)
- SECSEC Form S-8 filed by Banc of California Inc.S-8 - BANC OF CALIFORNIA, INC. (0001169770) (Filer)
- INSIDERDirector Rice Joseph J was granted 4,780 shares, increasing direct ownership by 22% to 26,417 units (SEC Form 4)4 - BANC OF CALIFORNIA, INC. (0001169770) (Issuer)
- INSIDERDirector Thau Andrew was granted 4,780 shares, increasing direct ownership by 12% to 46,282 units (SEC Form 4)4 - BANC OF CALIFORNIA, INC. (0001169770) (Issuer)
- INSIDERDirector Curran Mary A was granted 4,780 shares, increasing direct ownership by 81% to 10,663 units (SEC Form 4)4 - BANC OF CALIFORNIA, INC. (0001169770) (Issuer)
- INSIDERDirector Eggemeyer John M Iii was granted 4,780 shares, increasing direct ownership by 3% to 193,772 units (SEC Form 4)4 - BANC OF CALIFORNIA, INC. (0001169770) (Issuer)
- INSIDERDirector Eusey Shannon F was granted 4,780 shares, increasing direct ownership by 16% to 34,992 units (SEC Form 4)4 - BANC OF CALIFORNIA, INC. (0001169770) (Issuer)
- INSIDERDirector Schlogel Vania E was granted 4,780 shares, increasing direct ownership by 17% to 33,665 units (SEC Form 4)4 - BANC OF CALIFORNIA, INC. (0001169770) (Issuer)
- INSIDERDirector Lester Susan E was granted 4,780 shares, increasing direct ownership by 10% to 53,264 units (SEC Form 4)4 - BANC OF CALIFORNIA, INC. (0001169770) (Issuer)
- INSIDERDirector Burke Paul Robert was granted 4,780 shares, increasing direct ownership by 8% to 64,507 units (SEC Form 4)4 - BANC OF CALIFORNIA, INC. (0001169770) (Issuer)
- INSIDERDirector Barker James Andrew was granted 4,780 shares, increasing direct ownership by 11% to 48,907 units (SEC Form 4)4 - BANC OF CALIFORNIA, INC. (0001169770) (Issuer)
BANC FAQ
6 questionsWhat does Banc of California Inc. do?
Banc of California, Inc. operates as the bank holding company for Banc of California, National Association that provides banking products and services in the United States. The company offers deposit products, including checking, savings, money market, retirement, and interest-bearing and noninterest-bearing demand accounts, as well as certificate of deposits. It also provides various commercial and consumer loan products, such as commercial and industrial loans; commercial real estate and multifamily loans; construction loans; single family residential mortgage loans; warehouse and...Where does BANC stock trade?
Banc of California Inc. (BANC) is listed on NYSE.What sector and industry is BANC in?
Banc of California Inc. operates in the Finance sector, Major Banks industry.What are analysts saying about BANC?
Banc of California Inc. has had 8 recent analyst actions on file. The most recent action was from Wells Fargo: Overweight with a $2300.00 price target on 2026-08-10. Recent price targets range from $1800.00 to $2300.00.What companies are similar to BANC?
Notable peers in the same industry include JPM (JP Morgan Chase & Co.), BAC (Bank of America Corporation), WFC (Wells Fargo & Company), C (Citigroup Inc.), UBS (UBS Group AG Registered). Compare BANC side-by-side with any of them on Quantisnow.How can I track BANC on Quantisnow?
Quantisnow aggregates Banc of California Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow BANC to receive live email and push alerts on every new disclosure.